Significant shareholders:
| Shareholder/Beneficial Owner | Shares | % ISC |
|---|---|---|
| Lombard Odier Investment Managers | 145,587,281 | 15.05 |
| Canaccord Genuity Wealth Management | 110,541,761 | 11.43 |
| T Rowe Price Global Investments | 81,524,462 | 8.43 |
| Mr Richard Griffiths | 68,361,441 | 7.07 |
| Hargreaves Lansdown, stockbrokers | 67,628,895 | 6.99 |
| Interactive Investor | 54,358,829 | 5.62 |
| Janus Henderson Investors | 51,224,874 | 5.30 |
| Dr Andrew Nelson* | 46,266,881 | 4.78 |
as at 31 October 2024
Quoted: AIM (London Stock Exchange)
Other Exchanges / Trading Platforms: The Company is not listed on any other exchanges or trading platforms.
Number of securities in issue: 961,845,817 Ordinary shares.
Shares not in public hands: Insofar as the Company is aware, the percentage of securities that is not in public hands is 33.98%, these being held by directors, their families and significant shareholders.
Own shares held in treasury: The Company holds 4,115 Ordinary Shares in treasury.
Details on any restrictions on the transfer of securities: There are no restrictions on the transfer of securities.
Applicable code(s): The Company is subject to the UK City Code on Takeovers and Mergers. The Code is administered by The Panel and Takeovers in Mergers.
* Per the Company’s RNS announcement of 11 May 2020, 12,121,711 Ordinary Shares of Dr Nelson’s total beneficial interest are subject to a Sale and Repurchase Agreement with Equities First Holdings.